http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114028572-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114028572-B |
| titleOfInvention | New application of MAT2A inhibitors for the treatment of asthma |
| abstract | The present invention provides a new application of MAT2A inhibitors for the treatment of asthma. Specifically, the present invention provides the application of MAT2A inhibitors in the preparation of medicines for treating asthma or related diseases. The present invention also provides the application of the MAT2A inhibitor in the preparation of preparations for hindering the biosynthesis of the universal methyl donor S-adenosylmethionine to inhibit the function of type 2 natural lymphoid cells. The present invention also provides the application of a MAT2A inhibitor in the preparation of a preparation for inhibiting the function of type 2 natural lymphoid cells; preferably, the function of inhibiting type 2 natural lymphoid cells includes inhibiting or reducing the function of type 2 natural lymphoid cells Cellular type 2 cytokine expression. The present invention also provides the application of targeting the methionine cycle in screening and/or preparing medicines for treating asthma or related diseases. |
| priorityDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.